Is Humana really overvalued at its current price of around $247?

Valuation is all perspective right now. Based on Simply Wall St's analysis, the fair value of the stock is estimated to be $212.87, suggesting it is trading at a 16% premium to its intrinsic value. However, Humana trades at a discounted P/E ratio compared to industry peers such as UnitedHealth. If Humana restores its margins by 2027, the current price could become a strong long-term entry point.

Humana (HUM) Stock Valuation 2026: Is the Medicare Advantage Rally Sustainable?

Q: What is a Benefit Ratio and why is Humana's at 89.4 percent?

The Benefit Ratio, also known as the Medical Loss Ratio, is the percentage of premiums paid out in medical claims. Humana's Q1 ratio of 89.4% is slightly better than guidance but remains elevated because the company added 1.2 million new members in 2026. New members are generally more expensive during their first year before healthcare costs become efficiently managed.

Q: How do Star Ratings impact Humana’s stock price?

CMS assigns quality scores to Medicare plans called Star Ratings. Higher ratings allow insurers like Humana to receive larger government bonus payments. Humana recently faced a Star Ratings headwind that reduced these bonuses. Recovering 4-star and 5-star ratings is considered one of the biggest catalysts for improving profitability and achieving its long-term margin goals.

Q: Why is the expansion of CenterWell important?

CenterWell is Humana’s primary care and pharmacy division. By owning clinics and pharmacies that serve its members, Humana can better manage healthcare costs and improve efficiency. In 2026, Humana expanded CenterWell through the acquisition of MaxHealth, adding 54 new centers. This value-based care strategy reduces dependence on government reimbursement rates alone.

humana

The article from Simply Wall St explores Humana’s (HUM) valuation following a reduction in its full-year GAAP EPS guidance. It highlights a conflict between a "narrative" fair value of $212.87 (suggesting the stock is 16.1% overvalued) and traditional multiples like P/E, where Humana (at 26.3x) trades below its peers (32.4x) and its own historical "fair" ratio.

The core takeaway is that while Humana is seeing strong short-term price momentum (up ~25-27% in 90 days), it faces significant regulatory headwinds and margin compression within its Medicare Advantage (MA) business.

Below is a more comprehensive, uniquely titled analysis that synthesizes the financial data, regulatory context, and future outlook for a more complete picture.

The Medicare Tightrope: Balancing Humana’s Membership Surge Against Margin Decay

The Narrative Paradox: Price Momentum vs. Value Realism

Humana is currently a "tale of two tapes." On one hand, the stock has experienced a significant rally over the last three months, fueled by investor optimism and a stabilization in sentiment after a brutal 2024. On the other hand, the fundamental "fair value" remains under pressure due to a downward revision in GAAP (Generally Accepted Accounting Principles) earnings guidance.

While the stock trades around $247, quantitative models suggest a fair value closer to $212. This gap indicates that the recent rally might be "borrowing" from future growth, pricing in a recovery that hasn't fully materialized in the bottom line yet.

The Guidance Cut: Why GAAP and Adjusted EPS are Diverging

In its latest update, Humana trimmed its Full-Year 2026 GAAP EPS guidance to at least $8.36 (down from $8.89), while maintaining its Adjusted EPS at at least $9.00.

Why the gap?

Star Ratings Headwinds: A major driver for the profit squeeze is the decline in Medicare Star Ratings, which directly impacts the bonus payments Humana receives from the government.
The "New Member" Cost Curve: Humana is aggressively growing its Medicare Advantage (MA) footprint-expecting 25% growth. However, new members typically have higher initial medical costs before their care can be "managed" efficiently, leading to a temporary spike in the Benefit Ratio (currently at 89.4%).
Regulatory Compliance: The cost of doing business with the CMS (Centers for Medicare & Medicaid Services) has risen. Humana is treating compliance as an operational expense rather than a "checkbox," which protects against long-term legal risk but weighs on current margins.

Valuation Multiples: A Hidden Discount?

Despite the "overvalued" tag from some narrative models, Humana’s P/E ratio of 26.3x tells a different story when compared to the broader healthcare sector:

Industry Average: 22.4x (Humana is at a premium)
Peer Group Average (e.g., UnitedHealth, Elevance): 32.4x (Humana is at a discount)

This suggests that while Humana is more expensive than the average healthcare company, it is significantly cheaper than its direct competitors. Investors are essentially being asked to decide if they trust Humana’s "Value Creation Initiatives"-which aim to cut costs and scale the CenterWell primary care business-to close the earnings gap.

The Road to 2027: Key Catalysts to Watch

The bull case for Humana relies on its ability to hit a 3% Medicare Advantage margin by 2027. To get there, several things must go right:

Star Ratings Recovery: Reversing the quality rating decline is essential for high-margin revenue.
CenterWell Integration: Scaling its own primary care clinics (CenterWell) to capture more of the "value-based care" dollar.
Medical Cost Management: Stabilizing the benefit ratio as the massive wave of new members matures into the system.

Summary Table: Humana at a Glance

Metric	Status	Note
Market Sentiment	Bullish	Strong 90-day price momentum (~27%).
Short-term Valuation	Overvalued	Trading ~16% above "Narrative" fair value ($212).
Peer Comparison	Undervalued	Trading at 26.3x P/E vs Peer 32.4x.
Core Risk	High	CMS regulatory shifts and Star Rating volatility.
Growth Engine	Strong	25% individual Medicare Advantage membership growth.

Verdict: Humana is a high-reward, high-volatility play. The current price reflects a market that believes the worst of the Medicare Advantage "reset" is over, but the GAAP guidance cut serves as a sobering reminder that the path to margin recovery is still littered with regulatory hurdles.

Also read: How can I choose the best stock broker?

Frequently Asked Questions

Why did Humana cut its full year GAAP EPS guidance but kept its Adjusted EPS?

The downward revision in GAAP EPS (from $8.89 to at least $8.36) is primarily due to non-cash items and “value creation” costs, such as integrating new acquisitions (like MaxHealth) and restructuring costs. The adjusted EPS stays at $9.00, excluding these one-time “noise” items, offering what management views as a better look at the company’s fundamental operating health.

Is Humana really “overvalued” at its current price of ~$247?

Valuation is all perspective right now. Based on Simply Wall St's story, the fair value of the stock is estimated to be $212.87, suggesting it is trading at a 16% premium to its intrinsic value. For example, Humana trades at a discounted P/E ratio (26.3x vs 32.4x) versus industry peers such as UnitedHealth. If Humana manages to restore its margins by 2027, today’s price could turn out to be a good entry point.

What is a "Benefit Ratio" and why is Humana's at 89.4 percent?

The Benefit Ratio (or Medical Loss Ratio) is the percent of premiums that are paid out in medical claims. Humana's Q1 ratio of 89.4% is a little better than their guidance, but still high. That’s because Humana added 1.2 million new members (25 percent growth) in 2026. New members are more expensive in their first year, before their care is efficiently managed, squeezing profit margins temporarily.

How Do Star Ratings Impact Humana’s Stock Price?

The government assigns quality scores to Medicare known as Star Ratings. CMS (Centers for Medicare & Medicaid Services) pays big bonuses and gets high ratings. Humana recently experienced a “Star Ratings headwind” that lowered these bonuses. The recovery of 4-star and 5-star ratings is the most important catalyst for Humana to achieve its target of a 3% margin by 2028.

Why is the expansion of CenterWell important?

CenterWell is the primary care and pharmacy business of Humana. Humana owns the clinics and pharmacies that serve its members, so it can better control medical costs (the “Benefit Ratio”). In 2026, Humana acquired MaxHealth, adding 54 new centers to its network. The shift to “value-based care” is meant to make Humana less reliant on government insurance reimbursements alone.